YBX1 and melanoma: Silencing YB-1 induces cisplatin sensitization in neuroblastoma (Wang H. et al., 2017), esophageal SCC (Xu and Hu, 2016), bladder cancer (Shiota et al., 2011) and melanoma (Schittek et al., 2007).